Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Innovent Biologics Raises $260 Million in D Round, Setting a Record

publication date: Nov 29, 2016
Innovent Biologics of Suzhou raised $260 million in a Series D round, a record venture funding for a China biopharma company. The round brings Innovent's total fundraising to $410 million. The latest funding was led by China's State Development & Investment Corporation, a state-owned entity whose participation shows official China's interest in Innovent. Founded in 2011, Innovent is developing 12 biologic drugs, a combination of novel drugs and biosimilars. Four candidates are in clinical trials, three of them in Phase III. In 2015, Innovent sold ex-China rights for six oncology drug candidates to Lilly for $1 billion in upfront and milestone payments. More details....

Stock Symbol: (NYSE: LLY)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming Events

ChinaBio® Partnering Forum
September 10–11, 2024 | Shanghai, China
Register here

BIO-Europe®
November 4–6, 2024 | Stockholm, Sweden
Save €900 before September 13!
Register here

Biotech Showcase™
January 13–15, 2025 | San Francisco, CA
Save $600 before September 27!
Other Relevant Events

Antibody Engineering & Therapeutics Asia
October 21–23, 2024 | Kyoto, Japan
Save 30% with code CHINABIO30!
Register here